

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Mark E. Duggan, et al.	US/RO
Attorney Docket No.	21073YP	Authorized Officer: <u>Emily Bernhardt</u>
Filing Date:	October 4, 2004	
For:	INHIBITORS OF AKT ACTIVITY	

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

LETTER


Sir:

In compliance with 37 C.F.R. 1.821(f) of the Rules of Practice In Patent Cases: Application Disclosures Containing Nucleotide And/Or Amino Acid Sequences, the signature page and following statement are being submitted herewith.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. 1.821(c) and (e), respectively, are the same.

The enclosed diskette contains the Sequence Listing for case number 21073YP.

Respectfully submitted,

By: 

Matthew A. Leff
Registration No. 50,149
Attorney for Applicants

Merck & Co., Inc.
P.O. Box 2000 – RY 60-30
Rahway, New Jersey 07065-0907
Telephone No. (732) 594-1404

Date: October 4, 2004